“It is proposed that, thresholds of 108 mg/dL for FPG and concentration of 6% for [HbA1c] level could be used to define those who are at risk of retinopathy,” study researchers said….
Read More »Understanding Shared Medical Appointments, Part 1
An Introduction to Group Visits The complex needs of today’s patients present a challenge to medical group physicians who try to meet patients’ needs within the constraints of the traditional office visit. Studies show that the median length of a patient’s face-to-face time during an office visit with a primary …
Read More »Cost-Effectiveness Strategies, Part 1 of 4
Evaluation of the Kaiser Permanente Northern California population indicated that patients with diabetes are also very likely to have both dyslipidemia and hypertension….
Read More »OraMoist™
OraMoist is a breakthrough dry mouth patch that has been specially developed to alleviate parched, dry mouth, lock in moisture for hours, and restore a healthy oral environment. OraMoist is a small, tablet sized dry mouth moisturizer patch that adheres to the roof of the mouth or the inner cheek. …
Read More »Carb Counting vs. Glycemic Load to Determine Insulin Bolus?
How many carbs you eat might be less important for your blood sugar than your food’s glycemic load….
Read More »Old Mitochondria May be Responsible for Neuropathy in the Extremities
The finding may eventually lead to new ways to fight neuropathy, a condition that often accompanies other diseases including HIV/AIDS, diabetes and circulatory disorders….
Read More »Identifying Patients Who Can Benefit from Preventive Interventions
A1c and cardiovascular risk scores identify those who can benefit from preventive interventions, according to the ADDITION study….
Read More »Physician’s Empathy Associated with Positive Clinical Outcomes in Diabetic Patients
A physician’s empathy is an important factor associated with clinical competence….
Read More »Predicting the Best Response from Metformin via Genetic Markers
Common variants are associated with glycemic response to metformin in Type 2 diabetes….
Read More »Otelixizumab Developed by GSK and Tolerx Fails in Type 1 Diabetes Study
Tolerx, Inc., and GlaxoSmithKline (GSK) announced that the Phase 3 DEFEND-1 study of otelixizumab, an investigational humanized anti-CD3 monoclonal antibody, did not meet the primary efficacy endpoint of change in C-peptide at month 12 in patients with new-onset autoimmune Type 1 diabetes….
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.